Bixiye
P54-17 Clarification to Commercial Prior Authorization Requirements for Early Intensive Behavioral Intervention (EIBI)
Taariikhda uu dhaqangalayo barnaamijka: Okt 10, 2017
Natiijooyinka Raadinta
Soo bandhiga 3271 - 3280 ee natiijooyinka 4744
Bixiye
P23-18 Clinical Reviews for Court-Ordered Substance Use Disorder Treatment
Taariikhda wax ku ool ah ee barnaamijka: Jun 01, 2018
Bixiye
P2R1-18 Updated: New Medical Drug Prior Authorization Requirements for Voretigene Neparvovec (Luxturna)
Taariikhda uu dhaqangalayo Barnaamijka: : Abr 02, 2018
Bixiye
QP2-16 HEDIS Season Is Here
Taariikhda uu dhaqangalayo Barnaamijka: Jan 07, 2016
Bixiye
QP17-16 Claims with Attachments
Taariikhda dhaqangalka Barnaamijka: Jul 26, 2016
Bixiye
QP100-18 Pharmacy Benefit Exclusion for Crinone (progesterone) Gel, Finacea (alzelaic acid) Foam, Glatopa (glatiramer acetate) Injection
Taariikhda uu dhaqangalayo Barnaamijka: Nov 28, 2018
Bixiye
QP1-18 Transition of Care Management Features for New Medicare Advantage Prescription Drug Plans
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2018
Bixiye
QP11-16 New BlueRide Email Notification Option for SNF
Taariikhda uu dhaqangalayo Barnaamijka: May 04, 2016
Bixiye
QP44-17 New Pre-Authorization Form for Botulinum Toxin for Commercial Products
Taariikhda uu dhaqangalayo Barnaamijka: Des 05, 2017
Bixiye
QP12-17 Prior Authorization/Pre-Approval Forms Specific to Select Medical Policies
Taariikhda uu dhaqangalayo Barnaamijka: May 31, 2017